Anti mouse ifn γ clone xmg1

WT and A_2AR^−/− mice were treated (i.p.) with the monoclonal antibody anti-mouse IFN-γ clone XMG1.2 (BioXCell, West Lebanon, New Hampshire, EUA). Briefly, the mice were given 20 µg of antibody 1 day before and a second dose 24 h after the infection. From the fourth week post infection, the animals were treated with 10 µg every 3 days for 2 weeks thereafter. The control group was treated with an irrelevant mab IgG following the same schedule.

hyACE2 knock-in mice were vaccinated via intramuscular injection into the gastrocnemius muscle with 10 μg and 5 μg (28 days later) of SARS-CoV-2 full-length spike (S-2P) mRNA-LNP or luciferase mRNA-LNP^{54 (link)}. After 28 days, mice received an immunization boost with 5 μg SARS-CoV-2 S-2P mRNA-LNP or luciferase mRNA-LNP. SARS-Cov-2 S-2P mRNA vaccines were designed based on the SARS-CoV-2 full-length spike (S) protein sequence with K986P and V987P amino acids substitutions (Wuhan-Hu-1, GenBank: MN908947.3)^{38 (link)}.
For the experiments described in Fig. 6, mice were injected intravenously with 200 μg per mouse of anti-CD4 (clone GK1.5, BioXcell), anti-CD8 (clone YTS169.4, BioXcell) or both, three times 2 days apart. In addition, a group of mice was injected intravenously with 250 μg per mouse of anti-mouse IFN-γ (clone XMG1.2, BioXcell) two times, 4 h before and 3 days after the viral challenge.
In the experiments described in Fig. 4, mice were treated with 50 μg per mouse of Treg-Protector (anti-ARTC2 nanobody; clone: S + 16a; BioLegend, 149802) by intravenous injection 30 min before sacrificing them.

To estimate parasitemia, a drop of blood taken from the tail vein of each T. congolense-infected mouse on a microscopic slide was covered with cover slip, and parasitemia was determined by counting the number of parasites presents in at least 10 fields at 400× magnification of light microscope. During periods of heavy parasite load, estimation was done as described previously (42 (link)). For experiments requiring anti-IFN-γ treatment, mice were injected intraperitoneally with anti-mouse IFN-γ, clone XMG1.2, or control Ig (BioXcell) (1 mg/mouse).